CLAIMS

1. An antibody for use in a method of treating rheumatoid arthritis in a subject, comprising administering to the subject an effective amount of the antibody and methotrexate, wherein the antibody comprises the heavy chain variable region of sequence SEQ ID NO:2 and the light chain variable region of sequence SEQ ID NO:3 and the antibody is administered at between 100mg and 200 mg per two weeks, and wherein the subject (1) was previously treated for rheumatoid arthritis by administering methotrexate and (2) was previously ineffectively treated for rheumatoid arthritis by administering a TNF-α antagonist selected from the group consisting of etanercept, infliximab, adalimumab, golimumab and certolizumab pegol.
2. The antibody for use of claim 1, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administering methotrexate.
3. The antibody for use of claim 2, wherein methotrexate is administered between 6 to 25 mg per week.
4. The antibody for use of any of claims 1 to 3, wherein the antibody is administered at 150 mg per two weeks or 200 mg per two weeks.
5. The antibody for use of any of claims 1-4, wherein the subject achieves a 20% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.
6. The antibody for use of any of claims 1-4, wherein the subject achieves a 50% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.
7. The antibody for use of any of claims 1-4, wherein the subject achieves a 70% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.
8. The antibody for use of any of claims 1 to 3, wherein the subject has been treated with said anti-TNF-α antagonist for at least 3 months in the last 2 years or the subject was intolerant to at least one TNF-α antagonist.
9. The antibody for use of any of claims 1 to 8, wherein the antibody is sarilumab.
10. The antibody for use of any of claims 1 to 9, wherein the antibody is administered subcutaneously to the subject.